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EDITORIAL REVIEW
Anemia of end-stage renal disease (ESRD)
The association of anemia with both acute and chronic renal
failure has been recognized for over 100 years. It is a
hypoproliferative anemia with generally normocytic red cells
and is seen invariably when patients with ESRD become
symptomatic of uremia and require hemodialysis or peritoneal
dialysis. The association of anemia with the kidney is important
because this organ is responsible both for sensing oxygen
availability to tissues and for releasing erythropoietin (Ep) into
the circulation [1]. Under normal circumstances, a low level of
circulating Ep (10 to 30 milliunits/mi plasma) is capable of
maintaining a stable red cell mass [2]. Ep production, as
reflected by concentrations of the hormone in the urine and
plasma, may increase several-hundredfold in response to im-
paired oxygen delivery [1, 2]. Not surprisingly, then, Ep
production and the capacity of the kidney to respond to
impaired oxygen delivery are blunted when there is a decrease
in functional renal tissue. In general, the extent of renal
insufficiency in patients with ESRD is correlated directly with
the severity of anemia [3].
The anemia is important because it produces symptoms in
approximately one-half of the more than 200,000 patients on
dialysis world-wide and perhaps an equal number not yet
requiring dialysis. Only one-third of ESRD patients are reha-
bilitated by dialysis [4], the anemia being an important factor
contributing to fatigue and a sense of poor health.
Mechanisms of the anemia
The major mechanisms that have been recognized to contrib-
ute to the anemia of ESRD are a shortened red cell survival [5],
decreased Ep production (for the degree of anemia) [6], and
retained inhibitors or toxic metabolites in ESRD that inhibit
erythropoiesis [3, 7, 8]. Other recognized potential complica-
tions impairing marrow function are iron or folate deficiency [9,
10], aluminum toxicity [11—13], and the osteitis fibrosa associ-
ated with hyperparathyroidism [14].
Decreased red cell survival has been documented in ESRD
dialysis patients using isotope red cell tagging with 51Cr [15],
DF32P [16], '4C-cyanate [17], and measurements of carbon
monoxide exhalation [18]. The last technique, if properly con-
ducted, is extremely sensitive since the breakdown of one
molecule of heme releases one molecule of carbon monoxide.
In general, the hemolysis associated with ESRD is mild, with
red cell survival ranging from one-third normal to normal and
averaging approximately one-half normal [15—17]. The cause of
the shortened red cell survival appears to be extracellular since
the transfusion of normal red cells into uremic patients results
in a shortening of the survival of the transfused cells while
transfusion of red cells from patients with ESRD into non-
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uremic subjects is associated with normalization of red cell
survival [19]. Neither hemodialysis nor continuous ambulatory
peritoneal dialysis (CAPD) improves red cell survival [16, 20,
21]. In our opinion, hemolysis is not a major cause of anemia in
most patients since a normal erythroid marrow can compensate
easily for this degree of shortening of red cell survival. How-
ever, a subset of patients with ESRD develops chronic
hemolysis from hypersplenism with red cell survival of less than
one-fourth normal. These patients generally benefit from sple-
nectomy [22]. Acute hemolysis has been observed if a patient's
red cells are exposed during dialysis to various oxidants
[23—251, excessive formaldehyde in the dialysate [26], or over-
heated [27] or hypotonic dialysate [28]. This complication
should not occur with proper dialysis monitoring.
The most important cause of the anemia of ESRD is de-
creased Ep production. It has been known for over twenty
years that serum levels of Ep in patients with ESRD are well
below those of comparably anemic patients who have normal
renal function. What was not appreciated initially is that a
number of patients with ESRD have elevated levels of biolog-
ically active Ep, which can be demonstrated if large volumes of
plasma are concentrated. Caro et al concentrated plasma from
normal subjects and patients with ESRD approximately two-
hundredfold and assayed the plasma concentrates for Ep using
the polycythemic mouse bioassay. The patients with ESRD had
values well below the plasma Ep levels of patients with com-
parable degrees of anemia but without renal failure [29], and
most had values similar to normal subjects. However, approx-
imately 40% of patients with ESRD had elevated levels of
bioactive Ep. Thus, in these individuals, Ep deficiency was
relative. Unfortunately, quantitative studies of red cell produc-
tion in these patients were not carried out and it was not
possible to determine if increased erythropoiesis correlated
with the levels of plasma Ep.
More recently, the development of a reliable radio-
immunoassay (RIA) for Ep has revealed that some patients with
ESRD have elevated levels of immunoreactive Ep [3]. How-
ever, the usual correlation between the degree of anemia and
elevated levels of plasma Ep, as would be expected if renal
function were normal, is not seen [2]. These data cannot be
interpreted unambiguously because of the possibility that the
RIA is measuring immunoreactive, but not biologically active,
fragments of the Ep molecule. Consequently, normal or even
elevated levels of immunoreactive Ep in patients with ESRD
may be misleading.
In addition to decreased Ep production, inhibitors of
erythropoiesis have been postulated to be of significance in
patients with ESRD. In several cell systems, a uremic environ-
ment impairs cell proliferation, including the lymphocyte re-
sponse to mitogens [30], and in vitro erythropoiesis [31].
However, the evidence for inhibitors that may be contributing
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to the anemia of ESRD is both contradictory and controversial,
and the real role of inhibitors remains to be defined precisely.
There are several clinical settings that suggest strongly that
substances retained in ESRD interfere with erythroid marrow
function. The most convincing evidence was provided by Caro
who showed elevated levels of bioactive Ep in the plasma of a
number of patients with ESRD [291, This finding implies that the
marrow is unable to respond to the circulating Ep in these
individuals. Furthermore, a few patients placed on
hemodialysis [32] or switched to CAPD [331 have had a signif-
icant improvement in hemoglobin and hematocrit in the absence
of dramatic changes in plasma Ep levels, suggesting that an
inhibitor was removed by dialysis.
In contrast to these observations, there are several sugges-
tions why inhibitors, if present, are of little physiological
relevance. First, approximately 3% of dialysis patients normal-
ize their hematocrits spontaneously [34]. Second, those patients
who develop a hemolytic-uremic syndrome have high circulat-
ing Ep levels (measured by bioassay), may require dialysis, and
yet erythropoiesis typically is increased dramatically. Third,
bilateral nephrectomy in a stable patient maintained by
hemodialysis results in a decrease in effective erythropoiesis
and a fall in hematocrit [35]. This last finding would suggest that
even the low levels of Ep produced by the residual diseased
kidneys were capable of maintaining red cell production and
that the removal of this source of Ep resulted in further
impairment of erythropoiesis.
Part of the problem in defining the role of inhibitors in the
anemia of ESRD is the lack of appropriate control data that
would support the specificity of such inhibitors. For example,
early reports that parathyroid hormone might be responsible for
the inhibition of red cell production [36] could not be confirmed
when pure hormone or a synthetic peptide of a partial sequence
was tested in culture [371. When only partially purified parathy-
roid extract preparations were tested, inhibition of in vitro
hematopoiesis was not specific for red cells, and the extracts
inhibited in vitro granulopoiesis as well [37]. In concert with
this, McGonigle et al recently have reported a correlation
between parathyroid hormone levels, creatinine, and anemia in
a large group of patients with ESRD. When multivariate anal-
ysis was carried out, pärathyroid hormone levels failed to
correlate with the anemia [38].
Radtke et al have reported that the polyamine spermine might
contribute to the anemia of ESRD [39]. While this material
certainly appears to be inhibitory in vitro, Caro, Hickey, and
Erslev have provided preliminary evidence that this material, as
well, is not specific for erythropoiesis [40] and Spragg, Bentley,
and Coles have contested reports of elevated spermine levels in
the plasma of patients with ESRD [41]. Finally, Delwiche,
Eschbach, and Adamson have studied the effect of uremic
human sera on the in vitro growth of mouse granulocyte/mac-
rophage colony-forming cells, erythroid colony-forming cells,
and megakaryocytic colony-forming cells. Their results, while
confirming the presence of inhibitory substances in the sera of
patients with ESRD, failed to demonstrate specificity of the
inhibition and in vitro granulopoiesis, and megakaryopoiesis
were suppressed as well as erythropoiesis [42]. Since granulo-
cyte and platelet production usually are not impaired in patients
with ESRD, results of such inhibitor studies must be interpreted
cautiously. To demonstrate if such inhibitors are of physiologic
relevance, it will be necessary to correlate their presence with
the in vivo response of patients to Ep replacement therapy.
Other recognized contributors to the anemia of ESRD include
iron and folate deficiencies, osteitis fibrosa associated with
hyperparathyroidism, and aluminum toxicity. Iron deficiency is
prevalent particularly in non-transfused hemodialysis patients
because the small, repetitive blood losses associated with the
dialyzer may exceed the absorption of iron from the diet.
However, since iron absorption is normal and not impaired by
uremia [43, 44], iron supplementation should maintain iron
stores as long as blood loss from other body sites is not
excessive. Iron stores can now be evaluated easily and should
be monitored by serum ferritin determinations every 4 to 6
months [45] and either maintained or corrected by oral [46] or
parenteral iron administration. Since erythroid marrow function
is decreased in dialysis patients, the rate of marrow iron efflux
is reduced and, hence, iron stores must be decreased markedly
before erythroid function is impaired further. Therefore, iron
supplementation is rarely required until serum ferritin levels fall
below 30 ng/ml. Caution is advised in the use of parenteral iron
since anaphylactic reactions occur occasionally and the indis-
criminate administration of parenteral iron, without serum
ferritin monitoring, can lead to iron overload with tissue
siderosis. Such complications do not develop if oral iron is used
since the bowel mucosa will regulate iron absorption according
to the body's iron stores [45]. Iron overload, as defined by a
serum ferritin of greater than 300 nglml, is common in most
patients prior to the initiation of dialysis, unless there has been
excessive blood loss previously. This is because a significant
amount of body iron shifts from circulating red cells to the
reticuloendothelial system, as erythropoiesis decreases with
progressive renal disease. If parenteral iron administration,
either as iron dextran or in the form of blood transfusions,
exceeds the normal gastrointestinal mucosal iron and dialyzer
blood (iron) losses, then iron stores will increase. It is still
uncertain, however, whether severe iron overload results in
clinical problems in dialysis patients. In patients who do de-
velop iron overload, serum ferritin levels will fall as a result of
recurrent dialyzer blood losses if supplemental iron therapy is
discontinued. However, since many of these patients are trans-
fusion dependent, they will continue to be at risk from tissue
siderosis.
Folate deficiency may develop also in hemodialysis patients
who either restrict their protein intake (because folate dialysis
loss exceeds dietary intake) [10], or who require diphenylhy-
dantoin therapy. The presence of red cell macrocytosis suggests
folate deficiency, if iron overload is excluded [47]. Oral folic
acid therapy corrects or prevents this complication, however,
most dialysis patients ingest enough dietary folate to remain in
positive folate balance [48].
Osteitis fibrosa, a complication of hyperparathyroidism, may
reduce the erythroid marrow space and, thereby, the erythroid
cellular mass. Surgical [14] or medical [49] management may
reverse this complication. If marrow fibrosis becomes severe,
extramedullary hematopoiesis with splenomegaly may be seen.
This can lead to pancytopenia and increased red cell destruction
[50].
Aluminum toxicity is an extremely interesting and recently
noted complication of patients on hemodialysis. Not only does
aluminum toxicity result in dementia [51] and osteomalacia [52],
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Fig. 1. The correlation of serum Ep levels as measured by RIA in seven
normal and five anemic, uremic sheep. Anemia was induced in normal
sheep by phenyihydrazine and/or phlebotomy. (Reproduced from J Clin
Invest 74:434—441, 1984, with permission of the authors and publishers.)
Symbols are: •, normal; 0, anemic, uremic animals.
but it also results in microcytic red cells and accentuates the
anemia [11]. The osteomalacia appears to be reversed with
long-term deferoxamine therapy [52]. It is not clear at the
present time how aluminum induces microcytosis. Examination
of erythroid cells from the marrow of several patients with
aluminum-induced microcytosis, but with normal or elevated
iron stores, has disclosed absent or markedly reduced
sideroblasts, suggesting that aluminum in some way interferes
with the incorporation of iron into the erythroid cell for heme
synthesis. Of interest is the fact that the microcytosis reverses
quickly—within 1 or 2 months—following the institution of
weekly deferoxamine therapy. This occurs generally before
there is any improvement in the hematocrit. At present, the
magnitude, as well as the pathophysiology, of the toxic effects
of aluminum on the erythron remain to be determined, as does
the possibility that aluminum excess will interfere with
erythropoiesis if the marrow is stimulated by Ep.
Treatment and the future
To date, there has been no satisfactory treatment for the
anemia of ESRD. Only androgens have had any impact on the
anemia [53]; however, not all patients respond [54], the anemia
rarely is corrected, and side effects may be significant [55, 56].
Red cell transfusions have been the only sure way to correct the
symptoms of tissue hypoxia, but such therapy is only tran-
siently effective and transfusions increase the risk of exposure





Fig. 2. Correction of anemia in a uremic sheep by daily infusions of
Ep-rich plasma. The normal sheep hematocrit is 30 to 34. Polycythemia
was created by continued infusions. Each arrow represents 500 ml of
infused Ep-rich plasma. Abbreviation: WB, whole blood. (Reproduced
from J Clin Invest 74:434-441, 1984, with permission of the authors and
publishers.)
and iron overload. Erythroid marrow suppression may be
another effect of transfusion therapy, especially if multiple units
of red cells are infused at once [32]. Repeated transfusions thus
may make a patient transfusion dependent. Although there may
be only a relatively small amount of Ep produced by the
residual renal tissue, there is evidence that the usual Ep-
hematocrit feedback loop is intact [57]; this would explain the
marrow-suppressing effects of transfusions. Consequently,
while a liberal transfusion policy has been advocated to en-
hance the survival of renal transplants [58], caution is suggested
in view of these potential complications, and transfusions
should be reserved for those who clearly are symptomatic with
anemia or who are active candidates for a kidney transplant.
Fortunately, we are now on the verge of being able to
evaluate the effectiveness of Ep therapy in ESRD. Recently,
biotechnology firms have revealed that they have isolated the
human structural gene for Ep [59], the gene has been expressed,
and biologically active material from recombinant sources
should be available for testing in patients soon. This is a major
advance for a number of reasons, but is of particular importance
to patients with severe anemia and ESRD. Once animal and
human trials for safety and efficacy satisfy the governmental
regulatory agencies, recombinant Ep should be available for
therapy trials.
Will Ep be effective in these patients? This is of great interest
and concern, obviously. Recently, we have attempted to ad-
dress this question in a sheep model in which uremia was
produced by subtotal nephrectomy [60], Varying degrees of
uremia were induced and some animals required maintenance
hemodialysis; all had relative Ep deficiency (Fig. 1). When
these animals were treated with Ep-rich plasma, red cell pro-
duction increased, and the anemia was corrected in all (Fig. 2)
[61]. These results are encouraging, but the extent to which the
model resembles ESRD in humans remains to be seen. Never-
theless, if the results with the model are correct, we would
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anticipate that daily, or perhaps every-other-day, intravenous
doses of Ep will correct the anemia in ESRD. The minimum
amount of Ep required to maintain a normal red cell mass has
yet to be established, but may vary depending on the co-
existence of the complications mentioned earlier. Although Ep
replacement will add to the cost of the medical care of patients
with ESRD and anemia, at least some of the expense will be
offset by the elimination of transfusion requirements and andro-
gen therapy and a better rate of patient rehabilitation. Of
course, transfusion dependent dialysis patients will be the first
to be treated. What is less obvious, however, is the advantage
of treating patients who are not transfusion dependent, but who
have severe anemia with hematocrits in the 20 to 30% range.
Only through careful physiologic studies will it be possible to
determine the optimal red cell mass in such individuals.
The availability of large amounts of recombinant Ep that is
biologically active also presents investigators with the opportu-
nity to study kinetics of hormone clearance, alterations in the
physical state of Ep in the circulation of uremic or normal
humans, and to correlate in vitro studies of erythropoietic
inhibition with in vivo response. This last information will be
particularly relevant in validating the tests for inhibitors and in
predicting which patients might benefit from hormone replace-
ment therapy. It is possible that the anemia of ESRD may be an
endocrine deficiency state primarily, soon to be eliminated in
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